Added to YB: 2025-11-14
Pitch date: 2025-11-12
HROW [neutral]
Harrow, Inc.
-7.77%
current return
Author Info
No bio for this author
Upgrade to Yellowbrick Premium to unlock investor returns. Upgrade to Yellowbrick Premium
Company Info
Harrow, Inc., an eyecare pharmaceutical company, engages in the discovery, development, and commercialization of ophthalmic pharmaceutical products in the United States.
Market Cap
$1.3B
Pitch Price
$38.09
Price Target
N/A
Dividend
N/A
EV/EBITDA
29.74
P/E
-253.44
EV/Sales
5.49
Sector
Pharmaceuticals
Category
growth
Show full summary:
Harrow Health Inc. Earnings Update: A quick look
HROW (earnings): Q3 rev $71.6M (+45% YOY), driven by VEVYE $22.6M (+22% seq) & IHEEZO $21.9M (+20% seq). VEVYE market share doubled to 10.5%, secured major payer coverage for Jan 2026. TRIESENCE 4x growth since relaunch. 2025 guidance $270-280M vs prior $280M+. Strong growth at reasonable valuation.
Read full article (3 min)